The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Clinical Outcomes With Mavacamten Use in Patients With Obstructive Hypertrophic Cardiomyopathy Using Real-World Data
Abstract
Objective To examine the association of mavacamten therapy with cardiovascular outcomes compared with standard medical management in patients with obstructive hypertrophic cardiomyopathy (oHCM). Patients and methods The study population was identified using retrospective electronic health record data from the TriNetX network between April, 28th 2022 and August, 31st 2024. Appropriate International Classification of Diseases, Tenth Revision diagnosis codes and medication records were used to distinguish patients with oHCM receiving mavacamten from those receiving standard medical management. The primary outcome was a composite cardiovascular outcome, defined as the first occurrence of ventricular tachycardia, ventricular fibrillation, cardiac arrest, or all-cause mortality. The risk of the composite outcome with mavacamten therapy compared with standard medical management was estimated using a Cox model with inverse probability weighting. Results Among 12,784 patients with oHCM (6810 [53.3%] females; median age, 66 years [IQR, 55 to 74 years]), 550 and 12,234 patients were included in the mavacamten and standard medical management groups, respectively. There were 13 (2.4%) and 560 (4.6%) events of the composite outcome in the mavacamten and standard medical management groups, respectively. In the multivariable Cox proportional analysis utilizing inverse probability weighting, mavacamten therapy was associated with a significantly lower risk of composite outcome (hazard ratio,…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Stabilized weights were trimmed at the 1st and 99th percentiles.
“Stabilized weights were trimmed at the 1st and 99th percentiles [5].”
From Association of GLP-1 receptor agonist use with cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy (2026) · cites this paper as [5]
Citations
Cites
A global federated real-world data and analytics platform for research
Palchuk, M. B., London, J. W., Perez-Rey, D., Drebert, Z. J., Winer-Jones, J. P., Thompson, C. N., Esposito, J., & Claerhout, B. (2023) · JAMIA Open · doi:10.1093/jamiaopen/ooad035 · Cited by 831
Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001250 · Cited by 807
Neuen, B. L., Fletcher, R. A., Heath, L., Perkovic, A., Vaduganathan, M., Badve, S. V., Tuttle, K. R., Pratley, R., Gerstein, H. C., Perkovic, V., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.071689 · Cited by 168
Flagged first, then by citations
Research works printed but not linked: 25
- Olivotto, 2020, Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 396, 759, 10.1016/S0140-6736(20)31792-X · DOI · Paper page
- Toepfer, 2020, Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Published correction appears in Circulation. 2020;141(10):e645, Circulation, 141, 828, 10.1161/CIRCULATIONAHA.119.042339 · DOI
- Ommen, 2020, 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, J Am Coll Cardiol, 76, e159, 10.1016/j.jacc.2020.08.045 · DOI · Paper page
- Braunwald, 2023, Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy, Eur Heart J, 44, 4622, 10.1093/eurheartj/ehad637 · DOI
- Desai, 2023, Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial, JAMA Cardiol, 8, 968, 10.1001/jamacardio.2023.3342 · DOI
- Spertus, 2021, Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 397, 2467, 10.1016/S0140-6736(21)00763-7 · DOI · Paper page
- Wheeler, 2023, Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial, JAMA Cardiol, 8, 240, 10.1001/jamacardio.2022.5099 · DOI
- Heitner, 2019, Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial, Ann Intern Med, 170, 741, 10.7326/M18-3016 · DOI
- Heitner, 2019, Precision Pharmacological Treatment for Obstructive Hypertrophic Cardiomyopathy With Mavacamten: One-Year Results From PIONEER-OLE, Circulation, 140, A13962
- Garcia-Pavia, 2024, Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy, Eur Heart J, 45, 5071, 10.1093/eurheartj/ehae579 · DOI · Paper page
- Wang, 2024, Association of semaglutide with risk of suicidal ideation in a real-world cohort, Nat Med, 30, 168, 10.1038/s41591-023-02672-2 · DOI · Paper page
- Hasnie, 2023, Complications associated with transesophageal echocardiography in transcatheter structural cardiac interventions, J Am Soc Echocardiogr, 36, 381, 10.1016/j.echo.2022.12.023 · DOI
- Parcha, 2021, A retrospective cohort study of 12,306 pediatric COVID-19 patients in the United States, Sci Rep, 11, 10.1038/s41598-021-89553-1 · DOI
- Taquet, 2021, Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA, Lancet Psychiatry, 8, 130, 10.1016/S2215-0366(20)30462-4 · DOI · Paper page
- Altibi, 2023, Hospital procedural volume and clinical outcomes following septal reduction therapy in obstructive hypertrophic cardiomyopathy, J Am Heart Assoc, 12, 10.1161/JAHA.122.028693 · DOI
- Patlolla, 2023, Impact of race and ethnicity on use and outcomes of septal reduction therapies for obstructive hypertrophic cardiomyopathy, J Am Heart Assoc, 12, 10.1161/JAHA.122.026661 · DOI
- Rühle, 2023, Evaluation of concomitant systemic treatment in older adults with head and neck squamous cell carcinoma undergoing definitive radiotherapy, JAMA Netw Open, 6, 10.1001/jamanetworkopen.2023.0090 · DOI
- Chesnaye, 2021, An introduction to inverse probability of treatment weighting in observational research, Clin Kidney J, 15, 14, 10.1093/ckj/sfab158 · DOI
- Beinfeld, 2022, Mavacamten for hypertrophic cardiomyopathy: effectiveness and value, J Manag Care Spec Pharm, 28, 369
- Elliott, 2006, Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy, Eur Heart J, 27, 1933, 10.1093/eurheartj/ehl041 · DOI
- Abdelfattah, 2023, Mavacamten short-term hemodynamic, functional, and electrocardiographic outcomes: initial real-world post-trial experience, JACC Adv, 2, 10.1016/j.jacadv.2023.100710 · DOI
- Desai, 2022, Projecting the long-term clinical value of mavacamten for the treatment of obstructive hypertrophic cardiomyopathy in the United States: an assessment of net health benefit, Clin Ther, 44, 52, 10.1016/j.clinthera.2021.11.006 · DOI
- de Marvao, 2021, Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy, J Am Coll Cardiol, 78, 1097, 10.1016/j.jacc.2021.07.017 · DOI
- Semsarian, 2015, New perspectives on the prevalence of hypertrophic cardiomyopathy, J Am Coll Cardiol, 65, 1249, 10.1016/j.jacc.2015.01.019 · DOI
- Austin, 2017, The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes, Stat Methods Med Res, 26, 1654, 10.1177/0962280215584401 · DOI
Cited by
Sorted by citations
Bal, H. S., Nayak, A., Pampana, A., Malay, S., Upadhyaya, A., Vekariya, N., Arora, G., & Arora, P. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101451
Self-citation
Metadata
- Authors
- Patel, N., Gaonkar, M., Pampana, A., Shetty, N. S., Vekariya, N., Li, P., Arora, G., & Arora, P.
- ORCID
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2026-02
- Volume
- 101
- Issue
- 2
- Pages
- 284-294
- ISSN
- 0025-6196
- Cited by
- 2
- References
- 3
- Language
- en
- Licence
- Funders
- National Heart Lung and Blood Institute Division of Intramural Research (R01HL160982, R01HL163852, R01HL163081)
- National Institutes of Health
- National Heart, Lung, and Blood Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
